Oxford Asset Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Oxford Asset Management’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-35,547	Closed	-$169K	–	2110
2019 Q2	$169K	Sell	35,547 -52,953	-60%	-$251K	﹤0.01%	1575
2019 Q1	$484K	Sell	88,500 -16,089	-15%	-$74K	0.01%	1231
2018 Q4	$318K	Buy	104,589 +59,588	+132%	+$207K	0.01%	1377
2018 Q3	$185K	Sell	45,001 -29,136	-39%	-$123K	﹤0.01%	1611
2018 Q2	$287K	Buy	74,137 +14,596	+25%	+$96.9K	0.01%	1508
2018 Q1	$377K	Buy	+59,541	New	+$493K	0.01%	1338
2016 Q1	–	Sell	-5,379	Closed	-$342K	–	990
2015 Q4	$342K	Buy	+5,379	New	+$378K	0.01%	738

Other funds holding MACK

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return

WIM

Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Oxford Asset Management's MACK Position: Q3 2019 in Review

Oxford Asset Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2019, closing a stake of 35,547 shares — an estimated $169K sold.

Oxford Asset Management first reported a position in MACK in Q4 2015 and held it in 7 quarters. The position peaked at $484K in Q1 2019. 47 funds tracked by Wall St. Rank hold MACK as of Q3 2019.

Oxford Asset Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
Oxford Asset Management sold 35,547 Merrimack Pharmaceuticals, Inc. shares in Q3 2019, an estimated $169K.
Oxford Asset Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2015 and held it in 7 quarters.
Oxford Asset Management's Merrimack Pharmaceuticals, Inc. position peaked at $484K in Q1 2019.
47 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2019.

Based on Oxford Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.